Literature DB >> 26849891

Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data.

Hye-Lin Kim1,2, Dam Kim3,4, Eun Jin Jang5, Min-Young Lee1, Hyun Jin Song1, Sun-Young Park1, Soo-Kyung Cho3,4, Yoon-Kyoung Sung3,4, Chan-Bum Choi3,4, Soyoung Won4, So-Young Bang6, Hoon-Suk Cha7, Jung-Yoon Choe8, Won Tae Chung9, Seung-Jae Hong10, Jae-Bum Jun3, Jinseok Kim11, Seong-Kyu Kim8, Tae-Hwan Kim3, Tae-Jong Kim12, Eunmi Koh7, Hwajeong Lee8, Hye-Soon Lee6, Jisoo Lee13, Shin-Seok Lee12, Sung Won Lee9, Sung-Hoon Park8, Seung-Cheol Shim14, Dae-Hyun Yoo3, Bo Young Yoon15, Sang-Cheol Bae16,17, Eui-Kyung Lee18.   

Abstract

The aim of this study was to estimate the mapping model for EuroQol-5D (EQ-5D) utility values using the health assessment questionnaire disability index (HAQ-DI), pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) in a large, nationwide cohort of rheumatoid arthritis (RA) patients in Korea. The KORean Observational study Network for Arthritis (KORONA) registry data on 3557 patients with RA were used. Data were randomly divided into a modeling set (80 % of the data) and a validation set (20 % of the data). The ordinary least squares (OLS), Tobit, and two-part model methods were employed to construct a model to map to the EQ-5D index. Using a combination of HAQ-DI, pain VAS, and DAS28, four model versions were examined. To evaluate the predictive accuracy of the models, the root-mean-square error (RMSE) and mean absolute error (MAE) were calculated using the validation dataset. A model that included HAQ-DI, pain VAS, and DAS28 produced the highest adjusted R (2) as well as the lowest Akaike information criterion, RMSE, and MAE, regardless of the statistical methods used in modeling set. The mapping equation of the OLS method is given as EQ-5D = 0.95-0.21 × HAQ-DI-0.24 × pain VAS/100-0.01 × DAS28 (adjusted R (2) = 57.6 %, RMSE = 0.1654 and MAE = 0.1222). Also in the validation set, the RMSE and MAE were shown to be the smallest. The model with HAQ-DI, pain VAS, and DAS28 showed the best performance, and this mapping model enabled the estimation of an EQ-5D value for RA patients in whom utility values have not been measured.

Entities:  

Keywords:  DAS28; EQ-5D; HAQ-DI; Mapping; Utility

Mesh:

Year:  2016        PMID: 26849891     DOI: 10.1007/s00296-016-3427-1

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  43 in total

1.  AIC model selection using Akaike weights.

Authors:  Eric-Jan Wagenmakers; Simon Farrell
Journal:  Psychon Bull Rev       Date:  2004-02

2.  Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values.

Authors:  Mónica Hernández Alava; Allan J Wailoo; Roberta Ara
Journal:  Value Health       Date:  2012-03-23       Impact factor: 5.725

3.  A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes.

Authors:  Mónica Hernández Alava; Allan Wailoo; Fred Wolfe; Kaleb Michaud
Journal:  Med Decis Making       Date:  2013-09-11       Impact factor: 2.583

Review 4.  International comparisons in valuing EQ-5D health states: a review and analysis.

Authors:  Richard Norman; Paula Cronin; Rosalie Viney; Madeleine King; Deborah Street; Julie Ratcliffe
Journal:  Value Health       Date:  2009-08-20       Impact factor: 5.725

5.  Factors influencing quality of life (QOL) for Korean patients with rheumatoid arthritis (RA).

Authors:  Soo-Kyung Cho; Dam Kim; Jae-Bum Jun; Sang-Cheol Bae; Yoon-Kyoung Sung
Journal:  Rheumatol Int       Date:  2012-01-05       Impact factor: 2.631

6.  Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases.

Authors:  Myoung-Hee Kim; Young-Shin Cho; Wan-Sik Uhm; Sehyun Kim; Sang-Cheol Bae
Journal:  Qual Life Res       Date:  2005-06       Impact factor: 4.147

7.  Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.

Authors:  Chris Pease; Janet E Pope; Don Truong; Claire Bombardier; Jessica Widdifield; J Carter Thorne; Boulos Paul Haraoui; Eliofotisti Psaradellis; John Sampalis; Ashley Bonner
Journal:  Semin Arthritis Rheum       Date:  2010-12-17       Impact factor: 5.532

8.  Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis?

Authors:  I Castrejón; A M Ortiz; R García-Vicuña; J P Lopez-Bote; A Humbría; L Carmona; I Gonzalez-Alvaro
Journal:  Clin Exp Rheumatol       Date:  2008 Sep-Oct       Impact factor: 4.473

9.  Psychometric evaluation of a Korean Health Assessment Questionnaire for clinical research.

Authors:  S C Bae; E F Cook; S Y Kim
Journal:  J Rheumatol       Date:  1998-10       Impact factor: 4.666

Review 10.  Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP).

Authors:  Gillian A Hawker; Samra Mian; Tetyana Kendzerska; Melissa French
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

View more
  8 in total

1.  Mapping between HAQ-DI and EQ-5D-5L in a Chinese patient population.

Authors:  Thomas Patton; Hao Hu; Luan Luan; Keqin Yang; Shu-Chuen Li
Journal:  Qual Life Res       Date:  2018-07-04       Impact factor: 4.147

2.  Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis.

Authors:  Jas Bindra; Ishveen Chopra; John Niewoehner; Mary Panaccio; George J Wan
Journal:  Clinicoecon Outcomes Res       Date:  2021-05-06

3.  Association between follistatin-related protein 1 and the functional status of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Taejun Yoon; Sung Soo Ahn; Jung Yoon Pyo; Jason Jungsik Song; Yong-Beom Park; Sang-Won Lee
Journal:  Chin Med J (Engl)       Date:  2021-04-14       Impact factor: 2.628

Review 4.  Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement.

Authors:  Helen Dakin; Lucy Abel; Richéal Burns; Yaling Yang
Journal:  Health Qual Life Outcomes       Date:  2018-02-12       Impact factor: 3.186

5.  Predicting health-related quality of life (EQ-5D-5 L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP.

Authors:  Jasmine Peak; Ilias Goranitis; Ed Day; Alex Copello; Nick Freemantle; Emma Frew
Journal:  Health Qual Life Outcomes       Date:  2018-05-30       Impact factor: 3.186

6.  Strawberries Improve Pain and Inflammation in Obese Adults with Radiographic Evidence of Knee Osteoarthritis.

Authors:  Jace Schell; R Hal Scofield; James R Barrett; Biji T Kurien; Nancy Betts; Timothy J Lyons; Yan Daniel Zhao; Arpita Basu
Journal:  Nutrients       Date:  2017-08-28       Impact factor: 5.717

7.  Risk factors associated with inadequate control of disease activity in elderly patients with rheumatoid arthritis: Results from a nationwide KOrean College of Rheumatology BIOlogics (KOBIO) registry.

Authors:  Seung Min Jung; Seung-Ki Kwok; Ji Hyeon Ju; Sang-Won Lee; Jason Jungsik Song; Chong-Hyeon Yoon; Yong-Beom Park; Sung-Hwan Park
Journal:  PLoS One       Date:  2018-10-16       Impact factor: 3.240

8.  Health-related quality of life in patients with rheumatoid arthritis.

Authors:  Wanruchada Katchamart; Pongthorn Narongroeknawin; Wanwisa Chanapai; Phakhamon Thaweeratthakul
Journal:  BMC Rheumatol       Date:  2019-08-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.